Polycomb Genes Expression As a Predictor of Poor Clinical Outcome in Children with Medulloblastoma

Overview

Journal Childs Nerv Syst

Specialty Pediatrics

Date 2010 Aug 19

PMID 20717685

Citations 5

Authors

Magdalena Zakrzewska

Krzysztof Zakrzewski

Sylwia M Gresner

Sylwester Piaskowski

Beata Zalewska-Szewczyk

Pawel P Liberski

Affiliations

Soon will be listed here.

Abstract

Introduction: Medulloblastoma is the most frequent type of embryonal tumor in the pediatric population, accounting for 20-25% of all brain tumors in children. Recently, the suspected contribution of the Polycomb group (PcG) genes in medulloblastoma development was described. PcG genes play an important role in developmental processes; they are also involved in the self-renewal of hematopoietic and neural stem cells as well as in malignant transformation.

Purpose: In this study, we evaluated the expression of BMI1and PCGF2, members of family of PcG genes, and their potential target, MYC oncogene, and analyzed their association with demographic and clinical data.

Materials And Methods: Thirty-one children (18 males and 13 females, aged from 0.4 to 17 years) with medulloblastoma were included in this study. The gene's expression level was measured by quantitative real-time PCR, obtained using the two-color multiplexing technique.

Results: We found that the higher expression levels of BMI1 and PCGF2 genes were associated with significantly decreased patient survival (p = 0.02 and p = 0.012, respectively). Significant differences between gender were found, with a higher expression level of the PCGF2 gene observed among females (p = 0.02).

Conclusion: Our analysis showed correlation between BMI1 and PCGF2 gene's expression and survival in children with medulloblastoma.

Citing Articles

Epigenetic-Based Therapy-A Prospective Chance for Medulloblastoma Patients' Recovery.

Strejczek A, Woszczyk D, Urbaniak H, Rozanska M, Robak M, Matuszewska Z Int J Mol Sci. 2021; 22(9).

PMID: 34066495 PMC: 8124462. DOI: 10.3390/ijms22094925.

Co-inhibition of BMI1 and Mel18 enhances chemosensitivity of esophageal squamous cell carcinoma and .

Wang J, Ji H, Zhu Q, Yu X, Du J, Jiang Z Oncol Lett. 2019; 17(6):5012-5022.

PMID: 31186712 PMC: 6507449. DOI: 10.3892/ol.2019.10160.

Epigenetic regulation in medulloblastoma.

Yi J, Wu J Mol Cell Neurosci. 2017; 87:65-76.

PMID: 29269116 PMC: 5828953. DOI: 10.1016/j.mcn.2017.09.003.

Recent advances and future of immunotherapy for glioblastoma.

Kamran N, Calinescu A, Candolfi M, Chandran M, Mineharu Y, Asad A Expert Opin Biol Ther. 2016; 16(10):1245-64.

PMID: 27411023 PMC: 5014608. DOI: 10.1080/14712598.2016.1212012.

Epigenetic changes in pediatric solid tumors: promising new targets.

Lawlor E, Thiele C Clin Cancer Res. 2012; 18(10):2768-79.

PMID: 22589485 PMC: 3691809. DOI: 10.1158/1078-0432.CCR-11-1921.

References

Wang W, Lin T, Huang J, Hu W, Xu K, Liu J . Analysis of Mel-18 expression in prostate cancer tissues and correlation with clinicopathologic features. Urol Oncol. 2009; 29(3):244-51. DOI: 10.1016/j.urolonc.2009.02.004. View

Kajiume T, Ohno N, Sera Y, Kawahara Y, Yuge L, Kobayashi M . Reciprocal expression of Bmi1 and Mel-18 is associated with functioning of primitive hematopoietic cells. Exp Hematol. 2009; 37(7):857-866.e2. DOI: 10.1016/j.exphem.2009.04.011. View

Guo W, Datta S, Band V, Dimri G . Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell. 2006; 18(2):536-46. PMC: 1783768. DOI: 10.1091/mbc.e06-05-0447. View

Becker M, Korn C, Sienerth A, Voswinckel R, Luetkenhaus K, Ceteci F . Polycomb group protein Bmi1 is required for growth of RAF driven non-small-cell lung cancer. PLoS One. 2009; 4(1):e4230. PMC: 2626631. DOI: 10.1371/journal.pone.0004230. View

Glinsky G, Berezovska O, Glinskii A . Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest. 2005; 115(6):1503-21. PMC: 1136989. DOI: 10.1172/JCI23412. View

Das P, Puri T, Suri V, Sharma M, Sharma B, Sarkar C . Medulloblastomas: a correlative study of MIB-1 proliferation index along with expression of c-Myc, ERBB2, and anti-apoptotic proteins along with histological typing and clinical outcome. Childs Nerv Syst. 2009; 25(7):825-35. DOI: 10.1007/s00381-009-0884-9. View

Giangaspero F, Wellek S, Masuoka J, Gessi M, Kleihues P, Ohgaki H . Stratification of medulloblastoma on the basis of histopathological grading. Acta Neuropathol. 2006; 112(1):5-12. DOI: 10.1007/s00401-006-0064-x. View

Heard E . Recent advances in X-chromosome inactivation. Curr Opin Cell Biol. 2004; 16(3):247-55. DOI: 10.1016/j.ceb.2004.03.005. View

Aldosari N, Bigner S, Burger P, Becker L, Kepner J, Friedman H . MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med. 2002; 126(5):540-4. DOI: 10.5858/2002-126-0540-MAMOAI. View

10.

Rutkowski S, von Bueren A, von Hoff K, Hartmann W, Shalaby T, Deinlein F . Prognostic relevance of clinical and biological risk factors in childhood medulloblastoma: results of patients treated in the prospective multicenter trial HIT'91. Clin Cancer Res. 2007; 13(9):2651-7. DOI: 10.1158/1078-0432.CCR-06-1779. View

11.

Michael L, Westerman B, Ermilov A, Wang A, Ferris J, Liu J . Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion. Neoplasia. 2008; 10(12):1343-9, 5p following 1349. PMC: 2586685. DOI: 10.1593/neo.81078. View

12.

de Haas T, Hasselt N, Troost D, Caron H, Popovic M, Zadravec-Zaletel L . Molecular risk stratification of medulloblastoma patients based on immunohistochemical analysis of MYC, LDHB, and CCNB1 expression. Clin Cancer Res. 2008; 14(13):4154-60. DOI: 10.1158/1078-0432.CCR-07-4159. View

13.

Abdouh M, Facchino S, Chatoo W, Balasingam V, Ferreira J, Bernier G . BMI1 sustains human glioblastoma multiforme stem cell renewal. J Neurosci. 2009; 29(28):8884-96. PMC: 6665439. DOI: 10.1523/JNEUROSCI.0968-09.2009. View

14.

Wiederschain D, Chen L, Johnson B, Bettano K, Jackson D, Taraszka J . Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis. Mol Cell Biol. 2007; 27(13):4968-79. PMC: 1951487. DOI: 10.1128/MCB.02244-06. View

15.

Hayry V, Tanner M, Blom T, Tynninen O, Roselli A, Ollikainen M . Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol. 2008; 116(1):97-102. DOI: 10.1007/s00401-008-0376-0. View

16.

Eberhart C, Kratz J, Wang Y, Summers K, Stearns D, Cohen K . Histopathological and molecular prognostic markers in medulloblastoma: c-myc, N-myc, TrkC, and anaplasia. J Neuropathol Exp Neurol. 2004; 63(5):441-9. DOI: 10.1093/jnen/63.5.441. View

17.

Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S . BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001; 61(6):2409-12. View

18.

Pfaffl M, Horgan G, Dempfle L . Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res. 2002; 30(9):e36. PMC: 113859. DOI: 10.1093/nar/30.9.e36. View

19.

Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T . C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer. 2000; 89(5):395-402. View

20.

Dovey J, Zacharek S, Kim C, Lees J . Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion. Proc Natl Acad Sci U S A. 2008; 105(33):11857-62. PMC: 2575250. DOI: 10.1073/pnas.0803574105. View